Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

51.20
Delayed Data
As of 4:01pm ET
 -0.43 / -0.83%
Today’s Change
48.01
Today|||52-Week Range
66.58
-22.00%
Year-to-Date
Why Mylan's EpiPen Is Sparking "Epi-Rage"
10:43am / MotleyFool.com - Paid Partner Content
Why Momenta Pharmaceuticals Shares Made a Late-Day Jump Higher
Aug 24 / MotleyFool.com - Paid Partner Content
Teva Stock Gains, Leerink: Despite Patent Loss, No Generic Competition Until 2018
10:05am / TheStreet.com - Paid Partner Content
Mylan Falls After Being Called Out on Price Increases -- Should You Worry?
Aug 24 / TheStreet.com - Paid Partner Content
Mylan Is Done Leaning on EpiPen Sales and That Could be a Big Problem
9:53am / TheStreet.com - Paid Partner Content
Teva Stock Drops After Patent Invalidated
Aug 24 / TheStreet.com - Paid Partner Content
Mylan (MYL) Obtains Favorable USPTO Ruling for Copaxone
9:07am / Zacks.com - Paid Partner Content
A Backlash Materializes Against Soaring EpiPen Prices
Aug 23 / TheStreet.com - Paid Partner Content
Why EpiPen, Why Now: Analysts Explain the Timing of Mylan's Trouble
Aug 24 / TheStreet.com - Paid Partner Content
Swiss Generics Manufacturer Has Strong 1st Half of Year
Aug 22 / GuruFocus News - Paid Partner Content

Today’s Trading

Previous close51.63
Today’s open51.43
Day’s range51.11 - 52.29
Volume10,613,817
Average volume (3 months)6,269,759
Market cap$52.4B
Dividend yield2.66%
Data as of 4:01pm ET, 08/25/2016

Growth & Valuation

Earnings growth (last year)-48.62%
Earnings growth (this year)-5.51%
Earnings growth (next 5 years)+8.00%
Revenue growth (last year)-3.22%
P/E ratio34.4
Price/Sales2.89
Price/Book1.77

Competitors

 Today’s
change
Today’s
% change
BGNEBeiGene Ltd0.000.00%
OASMOasmia Pharmaceutica...-0.13-3.96%
VBLTVascular Biogenics L...+0.23+5.74%
DNAIProNAi Therapeutics ...0.000.00%
Data as of 4:00pm ET, 08/25/2016

Financials

Next reporting dateOctober 27, 2016
EPS forecast (this quarter)$1.36
Annual revenue (last year)$19.6B
Annual profit (last year)$1.6B
Net profit margin8.09%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
President, Chief Executive Officer &
Director
Erez Vigodman
President &
CEO-Global Operations
Carlo de Notaristefani
Corporate headquarters
Petach Tikva, Tel Aviv

Forecasts

Partner Offers

Search for Jobs